Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
16.10.2023 - Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and ...
The PALADIN study reported the intravitreal fluocinolone acetonide implant reduced the frequency of anti-VEGF injections in patients with diabetic macular edema out to 3 years.
FDA Commissioner Robert Califf said Thursday that misinformation, what he sees as one of the biggest issues facing his agency’s many jurisdictions, needs an equally expansive, overlapping approach.
Key Insights Institutions' substantial holdings in Alimera Sciences implies that they have significant influence over...
Caligan Partners LP (Trades, Portfolio), a New York-based investment firm, recently made a significant transaction in its portfolio. The firm reduced its stake in Alimera Sciences Inc, a commercial-stage pharmaceutical company. On September 14, 2023, Caligan Partners LP (Trades, Portfolio) reduced its holdings in Alimera Sciences Inc by 800,000 shares, representing a 4.54% change in the firm's portfolio.